A distinct metabolic response characterizes sensitivity to EZH2inhibition in multiple myeloma.

Nylund P. et al.

Multiple myeloma (MM) is a heterogeneous haematological disease that remains clinically challenging. Increased activity of the epigenetic silencer EZH2 is a common feature in patients with poor prognosis. Previous findings have demonstrated that metabolic profiles can be sensitive markers for response to treatment in cancer. While EZH2 inhibition (EZH2i) has proven efficient in inducing cell death in a number of human MM cell lines, we hereby identified a subset of cell lines that despite a global loss of H3K27me3, remains viable after EZH2i. By coupling liquid chromatography-mass spectrometry with gene and miRNA expression profiling, we found that sensitivity to EZH2i correlated with distinct metabolic signatures resulting from a dysregulation of genes involved in methionine cycling. Specifically, EZH2i resulted in a miRNA-mediated downregulation of methionine cycling-associated genes in responsive cells. This induced metabolite accumulation and DNA damage, leading to G2 arrest and apoptosis. Altogether, we unveiled that sensitivity to EZH2i in human MM cell lines is associated with a specific metabolic and gene expression profile post-treatment.

iDeal ChIP-seq Kit for Histones

Share this article

February, 2021


Products used in this publication

  • ChIP kit icon
    iDeal ChIP-seq kit for Histones
  • Bioruptor Pico
    Bioruptor® Pico 非接触式超声波破碎仪


  • IHEC Annual meeting 2022
    Quebec, Canada
    Oct 4-Oct 7, 2022
  • Danish RNA Society's 7th Annual Meeting on RNA
    Aarhus, Denmark
    Oct 11, 2022
  • ASHG 2022
    Los Angeles, California, USA
    Oct 25-Oct 29, 2022
  • International Conference on Epigenetics and Bioengineering 2022
    Houston, Texas, USA
    Oct 27-Oct 29, 2022
  • Long-Read Sequencing Meeting Uppsala LRUA22 Meeting
    Uppsala, Sweden
    Oct 31-Nov 2, 2022
  • Association for Molecular Pathology 2022
    Phoenix, Arizona, USA
    Nov 1-Nov 5, 2022



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics